bionaut labs

This LA-Based Biotech Company Made Remote-Controlled Devices to Treat Brain Tumors

A small group of scientists and engineers are developing a device smaller than a flea that will wind its way inside the heads of people with brain tumors and deliver life-saving treatments.

Bionaut Labs, a Los Angeles startup, unveiled on Wednesday the tiny rigid remote-controlled device with metallic parts, a silica polymer exterior and a cavity to place treatments inside. It's a sort of drone for the body.


"This is the revolution and this is where it starts," said physicist and co-founder Michael Shpigelmacher. "I have no doubt that 10 years forward, there will be not one, but there will be multiple companies in this universe of ... remote-controlled micro robots."

Bionaut Labs began preclinical trials in 2018 to treat brainstem glioma, a tumor nestled in one of the most complex and delicate areas of the body — the brainstem, which controls everything from breathing to eating to heart rate. Because of its location, surgery is often not an option and some patients undergo radiation therapy.

"You really want to hit up that tumor and you don't want to just flood the whole body with a payload that would have significant toxicity or side effects," Shpigelmacher said.

Their "micro robot" or "Bionaut," as the company calls it, is still untested in humans. But, the device is meant to be injected by doctors into the brain and controlled with a magnetic device that moves it through the brain and to the affected area. Once treatment is complete, it's removed magnetically. It's biggest advantage, the company hopes, is to deliver targeted treatment, eliminating the need for physicians to turn to more invasive medicines such as radiation.

Michael Shpigelmacher, Bionaut Labs

Physicist Michael Shpigelmacher is the co-founder of Bionaut Labs

"This is mostly useful for anatomical targets that are hard to reach where you need that level of anatomical precision," Shpigelmacher said.

He and his co-founders Aviad Maizels and Alex Shpunt previously worked together at a startup called PrimeScience that was later acquired by Apple in 2013. He began working with pharma companies in 2007, watching drugmakers formulate and reformulate drugs when they failed clinical trials.

Part of the problem is that medicine, most often pills, taken by patients flow through the bloodstream and often have side effects from depression and weight gain to even more serious ones. If it works, the Bionaut would only release chemicals to specific areas and not diffuse through a patient's bloodstream. That method, known as localized treatment, means drugs could be stronger and more targeted.

"That would maximize efficacy at the site of action, and minimize toxicity in all the places where it shouldn't have any activity," said Dr. Eunjoo Pacifici, a professor at the USC School of Pharmacy, about localized treatments.

But the process isn't easy. Drugs are highly regulated by the Food and Drug Administration. It can take years before a drug comes to market. Localized treatments often require a device to inject that treatment into the body. That, too, can take years for the FDA to approve.

"It's a combination product. Sometimes you need to have different parts of the FDA review that product as well. It's like developing two products at the same time," Pacifici said.

Bionauts are focused on brainstem glioma for now, but Shpigelmacher's background at McKinsey has him thinking big — the implications of Bionauts, he said, could change the way drugs are developed.

Pacifici said the drug-making process is a "high-stakes game" because companies often have to pump thousands of dollars into researching, developing and testing drugs without the promise of a return on investment. But if the FDA does not accept the benefit/ risk profile of a certain drug, it cannot get to the next step and be marketed or sold.

"You hope the product will do what you want it to do and there's some promising results in the lab, there's some promising results in the animals and the early stage clinical trials seem very promising," Pacifici said. "But then when you actually throw down the big money to conduct a big trial, more often than not it fails. A product can fail at any stage, but when it fails at a pivotal stage, it's a huge loss for the company."

If treatments can be localized, Shpigelmacher said, the amount of time companies spend in the research and development phase could shorten, and drugs would be conceptualized and tested to be used with a Bionaut.

The company raised $20 million in backing from Khosla Ventures, Upfront Ventures and Bold Capital.

Related Articles Around the Web
https://twitter.com/KeerthiVedantam
keerthi@dot.la

Subscribe to our newsletter to catch every headline.

Though Silicon Valley is still very much the capital of venture capital, Los Angeles is home to plenty of VCs who have made their mark – investing in successful startups early and reaping colossal returns for their limited partners.

Who stands out? We thought there may be no better judge than their peers, so we asked 28 of L.A.'s top VCs who impresses them the most.

Read more Show less
Ben Bergman

Ben Bergman is the newsroom's senior finance reporter. Previously he was a senior business reporter and host at KPCC, a senior producer at Gimlet Media, a producer at NPR's Morning Edition, and produced two investigative documentaries for KCET. He has been a frequent on-air contributor to business coverage on NPR and Marketplace and has written for The New York Times and Columbia Journalism Review. Ben was a 2017-2018 Knight-Bagehot Fellow in Economic and Business Journalism at Columbia Business School. In his free time, he enjoys skiing, playing poker, and cheering on The Seattle Seahawks.

The virtual influencer Miquela Sousa, aka Lil Miquela, whose rise has garnered equal parts uproar and admiration, continued her foray into NFTs on Wednesday with part two of a five-part series that promises to "tell a special story over time."

Read more Show less
Sam Blake

Sam primarily covers entertainment and media for dot.LA. Previously he was Marjorie Deane Fellow at The Economist, where he wrote for the business and finance sections of the print edition. He has also worked at the XPRIZE Foundation, U.S. Government Accountability Office, KCRW, and MLB Advanced Media (now Disney Streaming Services). He holds an MBA from UCLA Anderson, an MPP from UCLA Luskin and a BA in History from University of Michigan. Email him at samblake@dot.LA and find him on Twitter @hisamblake

https://twitter.com/hisamblake
samblake@dot.la
RELATEDTRENDING